

# Sanford D Markowitz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/176673/publications.pdf>

Version: 2024-02-01

60  
papers

6,974  
citations

172457

29  
h-index

128289

60  
g-index

64  
all docs

64  
docs citations

64  
times ranked

8554  
citing authors

#	ARTICLE	IF	CITATIONS
1	KILLER/DR5 is a DNA damage-induced p53-regulated death receptor gene. <i>Nature Genetics</i> , 1997, 17, 141-143.	21.4	1,005
2	Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. <i>Nature Genetics</i> , 1995, 9, 48-55.	21.4	759
3	Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. <i>Nature Genetics</i> , 1996, 13, 343-346.	21.4	580
4	Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. <i>Nature Genetics</i> , 2000, 26, 16-17.	21.4	420
5	Discovery of common and rare genetic risk variants for colorectal cancer. <i>Nature Genetics</i> , 2019, 51, 76-87.	21.4	377
6	Mad-related genes in the human. <i>Nature Genetics</i> , 1996, 13, 347-349.	21.4	359
7	Detection in Fecal DNA of Colon Cancer-Specific Methylation of the Nonexpressed Vimentin Gene. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1124-1132.	6.3	331
8	Sensitive digital quantification of DNA methylation in clinical samples. <i>Nature Biotechnology</i> , 2009, 27, 858-863.	17.5	317
9	Conversion of diploidy to haploidy. <i>Nature</i> , 2000, 403, 723-724.	27.8	248
10	E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. <i>Human Mutation</i> , 1999, 14, 249-255.	2.5	247
11	Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. <i>Science</i> , 2015, 348, aaa2340.	12.6	220
12	Physical activity and risks of breast and colorectal cancer: a Mendelian randomisation analysis. <i>Nature Communications</i> , 2020, 11, 597.	12.8	193
13	DNMT1-associated long non-coding RNAs regulate global gene expression and DNA methylation in colon cancer. <i>Human Molecular Genetics</i> , 2015, 24, 6240-6253.	2.9	167
14	HLTF gene silencing in human colon cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 4562-4567.	7.1	145
15	IL-33 activates tumor stroma to promote intestinal polyposis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2487-96.	7.1	141
16	Polymerase $\delta$ variants in RER colorectal tumours. <i>Nature Genetics</i> , 1995, 9, 10-11.	21.4	129
17	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 146-157.	6.3	129
18	Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	127

#	ARTICLE	IF	CITATIONS
19	Novel recurrently mutated genes in African American colon cancers. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1149-1154.	7.1	118
20	Chromosome number and structure both are markedly stable in RER colorectal cancers and are not destabilized by mutation of p53. Oncogene, 1998, 17, 719-725.	5.9	116
21	Epigenetic Alterations in the Gastrointestinal Tract: Current and Emerging Use for Biomarkers of Cancer. Gastroenterology, 2021, 160, 690-709.	1.3	112
22	Fucosylation Deficiency in Mice Leads to Colitis and Adenocarcinoma. Gastroenterology, 2017, 152, 193-205.e10.	1.3	48
23	Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 2021, 70, 1325-1334.	12.1	44
24	Aberrant Vimentin Methylation Is Characteristic of Upper Gastrointestinal Pathologies. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 594-600.	2.5	41
25	GNAS Mutations Identify a Set of Right-Sided, RAS Mutant, Villous Colon Cancers. PLoS ONE, 2014, 9, e87966.	2.5	39
26	Systems Biology Analyses Show Hyperactivation of Transforming Growth Factor- $\beta$ 2 and JNK Signaling Pathways in Esophageal Cancer. Gastroenterology, 2019, 156, 1761-1774.	1.3	38
27	Subtypes of Barrett's oesophagus and oesophageal adenocarcinoma based on genome-wide methylation analysis. Gut, 2019, 68, 389-399.	12.1	37
28	Colorectal cancers utilize glutamine as an anaplerotic substrate of the TCA cycle in vivo. Scientific Reports, 2019, 9, 19180.	3.3	37
29	The DNMT1-associated lincRNA DACOR1 reprograms genome-wide DNA methylation in colon cancer. Clinical Epigenetics, 2018, 10, 127.	4.1	34
30	Inactivating Mutation in the Prostaglandin Transporter Gene, <i>SLCO2A1</i> , Associated with Familial Digital Clubbing, Colon Neoplasia, and NSAID Resistance. Cancer Prevention Research, 2014, 7, 805-812.	1.5	29
31	Inhibitors of 15-Prostaglandin Dehydrogenase To Potentiate Tissue Repair. Journal of Medicinal Chemistry, 2017, 60, 3979-4001.	6.4	29
32	RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas. Cancer Research, 2016, 76, 5628-5633.	0.9	26
33	Association Between Germline Mutation in <i>VSIG10L</i> and Familial Barrett Neoplasia. JAMA Oncology, 2016, 2, 1333.	7.1	23
34	Biomarkers for Early Detection of Colorectal Cancer: The Early Detection Research Network, a Framework for Clinical Translation. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2431-2440.	2.5	23
35	A second-generation 15-PGDH inhibitor promotes bone marrow transplant recovery independently of age, transplant dose and granulocyte colony-stimulating factor support. Haematologica, 2018, 103, 1054-1064.	3.5	22
36	Chemopreventive Efficacy of the Cyclooxygenase-2 (Cox-2) Inhibitor, Celecoxib, Is Predicted by Adenoma Expression of Cox-2 and 15-PGDH. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 728-736.	2.5	19

#	ARTICLE	IF	CITATIONS
37	Mismatch repair-signature mutations activate gene enhancers across human colorectal cancer epigenomes. <i>ELife</i> , 2019, 8, .	6.0	19
38	Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers. <i>Oncogene</i> , 2001, 20, 1005-1009.	5.9	17
39	Therapeutic targeting of 15-PGDH in murine pulmonary fibrosis. <i>Scientific Reports</i> , 2020, 10, 11657.	3.3	17
40	Massively Parallel Sequencing of Esophageal Brushings Enables an Aneuploidy-Based Classification of Patients With Barrett's Esophagus. <i>Gastroenterology</i> , 2021, 160, 2043-2054.e2.	1.3	17
41	Prostaglandin dehydrogenase is a target for successful induction of cervical ripening. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6427-E6436.	7.1	16
42	Molecular Imaging of Colorectal Tumors by Targeting Colon Cancer Secreted Protein-2 (CCSP-2). <i>Neoplasia</i> , 2017, 19, 805-816.	5.3	15
43	Increased transversions in a novel mutator colon cancer cell line. <i>Oncogene</i> , 1998, 16, 1125-1130.	5.9	13
44	Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2486-2494.	2.5	13
45	Nuclear translocation of p85 <sup>12</sup> promotes tumorigenesis of PIK3CA helical domain mutant cancer. <i>Nature Communications</i> , 2022, 13, 1974.	12.8	13
46	Inhibition of 15-PGDH prevents ischemic renal injury by the PGE <sub>2</sub> /EP <sub>4</sub> signaling pathway mediating vasodilation, increased renal blood flow, and increased adenosine/A <sub>2A</sub> receptors. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, F1054-F1066.	2.7	12
47	Methylated <i>B3GAT2</i> and <i>ZNF793</i> Are Potential Detection Biomarkers for Barrett's Esophagus. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1890-1897.	2.5	11
48	A nonrandomized trial of vitamin D supplementation for Barrett's esophagus. <i>PLoS ONE</i> , 2017, 12, e0184928.	2.5	11
49	Colorectal Neoplasia Goes with the Flow: Prostaglandin Transport and Termination: Fig. 1. <i>Cancer Prevention Research</i> , 2008, 1, 77-79.	1.5	10
50	Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 727-735.	2.5	10
51	Inhibition of 15-PGDH Protects Mice from Immune-Mediated Bone Marrow Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1552-1556.	2.0	8
52	Adverse Clinical Outcome Associated With Mutations That Typify African American Colorectal Cancers. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw164.	6.3	7
53	Cancer bypasses the lymph nodes. <i>Science</i> , 2017, 357, 35-36.	12.6	7
54	15-Hydroxyprostaglandin dehydrogenase inhibitor prevents contrast-induced acute kidney injury. <i>Renal Failure</i> , 2021, 43, 168-179.	2.1	5

#	ARTICLE	IF	CITATIONS
55	ENVE: a novel computational framework characterizes copy-number mutational landscapes in colorectal cancers from African American patients. <i>Genome Medicine</i> , 2015, 7, 69.	8.2	2
56	A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. <i>PLoS ONE</i> , 2016, 11, e0146435.	2.5	2
57	15-PGDH regulates hematopoietic and gastrointestinal fitness during aging. <i>PLoS ONE</i> , 2022, 17, e0268787.	2.5	2
58	Reply to Ashktorab et al.: Mutational landscape of colon cancers in African Americans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E2853-E2853.	7.1	1
59	Structural Insights into Novel 15-Prostaglandin Dehydrogenase Inhibitors. <i>Molecules</i> , 2021, 26, 5903.	3.8	1
60	Polymer Microparticles Prolong Delivery of the 15-PGDH Inhibitor SW033291. <i>Pharmaceutics</i> , 2022, 14, 85.	4.5	0